Now available for Arizona patients! Non-invasive Smart Stickers™ that lift skin cells to test for certain genomic markers associated with melanoma.
LA JOLLA, CA and PHOENIX, November 15, 2022–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a noninvasive skin genomics platform, today announced today an agreement with Sonora Quest Laboratories (Sonora Quest), Arizona’s leading diagnostic laboratory, to expand access to improved melanoma detection. As a result of this agreement, Sonora Quest will be the exclusive lab in Arizona to offer the DermTech melanoma test to its extensive network of healthcare providers.
The DermTech Melanoma Test uses a non-invasive Smart Sticker™ to lift skin cells from the surface of a patient’s skin to test for certain genomic markers associated with melanoma. It excludes melanoma with a reliability of more than 99%. The agreement between DermTech and Sonora Quest will increase the availability of the DermTech melanoma test to Arizonans through a visit to their healthcare providers within the Sonora Quest network. Not only will this provide additional patient populations with increased access to the DermTech melanoma test, but it could also reduce the number of unnecessary biopsies and referrals to specialists and reduce costs to the healthcare system.
“This agreement with Sonora Quest demonstrates our continued commitment to help end melanoma deaths,” said John Dobak, MD, CEO of DermTech. “Given the frequency of patients asking their healthcare providers about suspicious moles, it is essential to introduce an easy way for providers to confidently rule out melanoma. We look forward to working with Sonora Quest to reach more patients who see their healthcare providers on the front line of defense.”
“Arizonans spend a lot of time outdoors, potentially putting us at increased risk for skin cancer,” said David A. Dexter, president and CEO of Sonora Quest. “Early detection is key and our agreement with DermTech will provide greater access to this innovative testing method to detect melanoma. We are committed to continually investing in innovative technology like this to make healthcare more convenient and deliver better outcomes for all Arizonans.
One of the deadliest forms of skin cancer, melanoma is most treatable when diagnosed early – in fact, the survival rate is 99% when detected early and only 27% once detected. time it spreads over a distance.
To learn more about Sonora Quest, visit https://www.sonoraquest.com/. To learn more about DermTech, visit https://dermtech.com/.
About Sonora Quest Laboratories
Sonora Quest Laboratories, an Arizona-based joint venture between Banner Health and Quest Diagnostics (NYSE:DGX), is one of the nation’s largest integrated laboratory systems. We are the trusted leader in diagnostic and information services with approximately 3,800 employees performing more than 97 million diagnostic tests annually. Our comprehensive testing menu includes routine, molecular, prescription drug monitoring, genetic/genomic, women’s health and pathology testing services. Sonora Quest is accredited by the College of American Pathologists, the gold standard in laboratory accreditation, which helps ensure the highest level of care for laboratory operations. To schedule an appointment, find one of our more than 70 Patient Service Centers across Arizona, or learn more about ordering tests without ordering from a provider through My Lab ReQuest™, visit- us at SonoraQuest.com. For press inquiries: [email protected]
About Derma Tech
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, made possible by its non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions of people by providing non-invasive, precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using its Smart Stickers™. DermTech markets and develops products that facilitate the early detection of skin cancers and develops products that assess inflammatory diseases and personalize drug treatments. For more information, please visit DermTech.
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. DermTech’s expectations, estimates and projections may differ from its actual results and, accordingly, you should do not rely on these forward-looking statements as predictions of future events. Words such as “expect”, “estimate”, “project”, “budget”, “plan”, “outlook”, “anticipate”, “intend”, “plan”, “may”, “will”, “could”, “should”, “believes”, “predicts”, “potential”, “continues” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, but are not limited to, expectations and assessments regarding: performance, patient benefits, profitability, commercialization and adoption of DermTech’s products and the market opportunity for such products, DermTech’s positioning and potential revenue growth, financial outlook and future financial performance, ability to maintain or improve operational efficiency, implications and interpretations of any study results, expectations regarding reimbursement models or Medicare fundraising from commercial payers and related billing practices or number of lives covered, and DermTech’s ability to expand its product offerings and develop ongoing products. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are beyond DermTech’s control and are difficult to predict. Factors that could cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be brought against DermTech; (2) DermTech’s ability to obtain additional financing to develop and commercialize its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) reimbursement for DermTech’s tests by Medicare and commercial payers; (5) the ability of patients or healthcare providers to obtain sufficient coverage or reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain key employees; (7) changes in applicable laws or regulations; (8) market adoption and demand for DermTech’s products and services as well as the possibility that DermTech may be adversely affected by other economic, business and/or competitive factors; and (9) other risks and uncertainties included in the “Risk Factors” section of DermTech’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), and other documents filed or to be filed by DermTech with the SEC, including any subsequent filings. DermTech cautions that the above list of factors is not exclusive. You should not place undue reliance on forward-looking statements, which speak only as of the date made. DermTech neither undertakes nor accepts any obligation or undertaking to publicly release updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances about which any such statement is made. based.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20221115005567/en/